Genewity B.V. is a recently founded biotech company based in Leiden, the Netherlands. Closely collaborating with the LUmc, we build on successes of our scientific and business teams in cell and gene therapies, including the first multi-centric clinical trial for gene therapy in the EU (the RAG1 SCID trial). Genewity has been founded to commercialize another potentially groundbreaking therapy for developing autologous thymus tissue de novo. Genewity is currently in a preclinical development stage and is engaged in raising a Series A to push the technology to the clinic.